Scholars Central

Conference abstractPublished 7 Dec 2015

BP-C1 in treatment of Metastatic Breast Cancer; A randomised, double blinded and placebo controlled clinical study

Authors: Stig Larsen

Norwegian University of Life Science, Oslo Norway

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Aim: The aim was to compare the efficacy and tolerability of a new benzene-poly-carboxylic acids complex with cisdiammineplatiumrn(II) (BP-C1) versus equal looking placebo in treatment of metastatic breast cancer patients. Material & Methods: A randomized, double blind, placebo controlled multi-center study was performed with semi-cross-overrndesign. Patients allocated to placebo switches to BP-C1 after 32 days of treatment. Thirty patients were given daily intramuscularrninjection of 0.035 mg/kg bw BP-C1 or placebo in 32 days. Biochemistry, hematology, NCI Bethesda (CTC-NCI), EORTCrnQOL-C30 & BR23 recorded at screening and after every 16 days of treatment. CT performed at screening and every 32nd day.rnResults: The sum of target lesions increased 2.4% in the BP-C1 group and 14.3% in placebo. The increase in the placebo grouprnwas significant (p=0.013) but not in BP-C1. The difference between the group was significant in favor of BP-C1 (p=0.04).rnSignificant difference (p=0.026) in favor of BP-C1 regarding RECIST classification. CTC-NCI toxicity score increased nonsignificantlyrnin the BP-C1 group, but significantly in placebo (p=0.05). “Breast cancer related pain and discomfort” and “Breastrncancer treatment problem last week” were significantly reduced (p=0.02) in the BP-C1 group and slightly increased in placebo.rnSignificant difference in favor of BP-C1 (p=0.05). “Breast cancer treatment problem last week” was significantly reduced in thernBP-C1 group (p=0.02) and slightly increased in placebo. “Breast cancer related pain and discomfort”.rnConclusion: BP-C1 reduces the cancer growth, is well tolerated, improves quality-of-life and has few mainly mild AE inrnpatients suffering from stage IV MBC

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Stig Larsen”